Abstract

The modified purine nucleotide 8-oxo-guanosine-2′-phosphate binds at the pyrimidine binding site of ribonuclease-A. The O8-2′GMP inhibitor is in a syn conformation, with an intramolecular hydrogen bond between the N-3 atom of the base and the O-5′ atom of the ribose. The essential groups of the protein involved in base recognition are Oγ45 and N-45, which form hydrogen bonds to the five-membered ring of the heterocyclic base. Mobility of enzyme side-chains (viz. LyThe modified purine nucleotide 8-oxo-guanosine-2′-phosphate binds at the pyrimidine binding site of ribonuclease-A. The O8-2′GMP inhibitor is in a syn conformation, with an intramolecular hydrogen bond between the N-3 atom of the base and the O-5′ atom of the ribose. The essential groups of the protein involved in base recognition are Oγ45 and N-45, which form hydrogen bonds to the five-membered ring of the heterocyclic base. Mobility of enzyme side-chains (viz. LyThe modified purine nucleotide 8-oxo-guanosine-2′-phosphate binds at the pyrimidine binding site of ribonuclease-A. The O8-2′GMP inhibitor is in a syn conformation, with an intramolecular hydrogen bond between the N-3 atom of the base and the O-5′ atom of the ribose. The essential groups of the protein involved in base recognition are Oγ45 and N-45, which form hydrogen bonds to the five-membered ring of the heterocyclic base. Mobility of enzyme side-chains (viz. LyThe modified purine nucleotide 8-oxo-guanosine-2′-phosphate binds at the pyrimidine binding site of ribonuclease-A. The O8-2′GMP inhibitor is in a syn conformation, with an intramolecular hydrogen bond between the N-3 atom of the base and the O-5′ atom of the ribose. The essential groups of the protein involved in base recognition are Oγ45 and N-45, which form hydrogen bonds to the five-membered ring of the heterocyclic base. Mobility of enzyme side-chains (viz. Lys41, Lys66, Hisl119) close to the catalytic cleft of the protein allows conformational flexibility in the substrate binding region of ribonuclease-A. Inhibitor binding alters the solvent structure of the protein but the overall shape of the enzyme is not effected.1, Lys66, Hisl119) close to the catalytic cleft of the protein allows conformational flexibility in the substrate binding region of ribonuclease-A. Inhibitor binding alters the solvent structure of the protein but the overall shape of the enzyme is not effected.1, Lys66, Hisl119) close to the catalytic cleft of the protein allows conformational flexibility in the substrate binding region of ribonuclease-A. Inhibitor binding alters the solvent structure of the protein but the overall shape of the enzyme is not effected.1, Lys66, Hisl119) close to the catalytic cleft of the protein allows conformational flexibility in the substrate binding region of ribonuclease-A. Inhibitor binding alters the solvent structure of the protein but the overall shape of the enzyme is not effected.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.